European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies Assessed in a Real-World Non-Interventional Study (EUCHARIS)
Latest Information Update: 01 Apr 2024
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms EUCHARIS
- Sponsors Pfizer
- 25 Mar 2024 Status changed from recruiting to completed.
- 01 Aug 2023 Status changed from active, no longer recruiting to recruiting.
- 03 May 2023 Planned End Date changed from 30 Mar 2023 to 29 Mar 2024.